CG Oncology, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 48.61 million compared to USD 35.44 million a year ago. Basic loss per share from continuing operations was USD 15.65 compared to USD 11.71 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.71 USD | +9.07% | +9.11% | 0.00% |
24/05 | Sector Update: Health Care Stocks Softer in Friday Afternoon Trading | MT |
24/05 | CG Oncology Shares Jump After Potential Combination Therapy for Bladder Cancer Meets Phase 2 Primary Endpoint | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 217.98Cr | |
+67.53% | 6.39TCr | |
-0.77% | 4.18TCr | |
+45.66% | 4.07TCr | |
-10.72% | 2.71TCr | |
+13.30% | 2.65TCr | |
-22.79% | 1.87TCr | |
+4.70% | 1.27TCr | |
+24.10% | 1.21TCr | |
+27.41% | 1.21TCr |
- Stock Market
- Equities
- CGON Stock
- News CG Oncology, Inc.
- CG Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023